Tet2 is required to resolve inflammation by recruiting Hdac2 to specifically repress IL-6
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index; 1 of the 24 sources its claims cite were checked for support.
Abstract
Epigenetic modifiers have fundamental roles in defining unique cellular identity through the establishment and maintenance of lineage-specific chromatin and methylation status. Several DNA modifications such as 5-hydroxymethylcytosine (5hmC) are catalysed by the ten eleven translocation (Tet) methylcytosine dioxygenase family members, and the roles of Tet proteins in regulating chromatin architecture and gene transcription independently of DNA methylation have been gradually uncovered. However, the regulation of immunity and inflammation by Tet proteins independent of their role in modulating DNA methylation remains largely unknown. Here we show that Tet2 selectively mediates active repression of interleukin-6 (IL-6) transcription during inflammation resolution in innate myeloid cells, including dendritic cells and macrophages. Loss of Tet2 resulted in the upregulation of several inflammatory mediators, including IL-6, at late phase during the response to lipopolysaccharide challenge. Tet2-deficient mice were more susceptible to endotoxin shock and dextran-sulfate-sodium-induced colitis, displaying a more severe inflammatory phenotype and increased IL-6 production compared to wild-type mice. IκBζ, an IL-6-specific transcription factor, mediated specific targeting of Tet2 to the Il6 promoter, further indicating opposite regulatory roles of IκBζ at initial and resolution phases of inflammation. For the repression mechanism, independent of DNA methylation and hydroxymethylation, Tet2 recruited Hdac2 and repressed transcription of Il6 via histone deacetylation. We provide mechanistic evidence for the gene-specific transcription repression activity of Tet2 via histone deacetylation and for the prevention of constant transcription activation at the chromatin level for resolving inflammation.
Overview
CoChat Summary
TL;DR
Tet2 actively represses Il6 transcription during the late phase of LPS-driven inflammation in myeloid cells by recruiting Hdac2 to the Il6 promoter, independent of DNA methylation. Tet2 loss prolongs IL-6 production and worsens endotoxin shock and DSS-induced colitis in mice.
Key findings
- In Tet2-deficient or Tet2-silenced dendritic cells and macrophages, the early LPS-induced rise in Il6 mRNA before 4 h was largely unchanged, but after 8 h Il6 mRNA remained elevated while control cells declined; IL-6 protein also increased, whereas Tnfa levels were similar. Tet3 silencing barely affected Il6.
- Tet2-deficient mice produced more IL-6 after systemic LPS, especially late, and showed worse lung tissue damage; in DSS colitis they had greater weight loss, higher IL-6, more inflammatory cell infiltration, and mucosal disruption. In Tet2-deficient BMDC, 22 genes were downregulated and 13 upregulated; 12 of the upregulated genes were TLR-induced, including Il6.
- IκBζ interacted with Tet2 and was required for Tet2 binding to the Il6 promoter at late LPS phase. IκBζ overexpression increased Il6 early but reduced it late, and Tet2 loss impaired this late repression.
- Tet2 associated with Hdac1/Hdac2 through its core-DSBH domain. Hdac2 binding at the Il6 promoter fell early and returned late; Hdac2 knockdown increased Il6 transcription and histone acetylation at 10 h, with Hdac1 compensation by 12 h. Catalytically mutant Tet2 still repressed Il6, and Tet2 loss reduced Hdac2 binding and late histone deacetylation.
Methods
- Mouse models included C57BL/6, Tet2fl/fl, Tet2-deficient, and Lyz2-Cre myeloid-specific Tet2-deficient mice; human monocytes came from healthy donors. Cells studied included BMDC, BMM, peritoneal macrophages, and splenic T, B, and NK cells, with LPS at 100 ng/ml; in vivo models were endotoxin shock and DSS colitis.
- Assays included RNA-seq, qPCR, ELISA, immunoblot, immunoprecipitation, co-IP with LC-MS/MS, ChIP and re-ChIP, luciferase reporters, siRNA knockdown, overexpression, and a GAL4-based recruitment assay.
- Statistics used unpaired Student’s t-tests with *P < 0.05 and P < 0.01; error bars were s.e.m. or s.d.; data were from triplicate technical or biological replicates and representative of three independent experiments.
Limitations
- The paper states that animal studies did not randomize by weight or sex and did not use blinding, and that sample size was not predetermined by a statistical method. It also states that HEK293T cells were not authenticated or tested for mycoplasma.
- Evident from the text: Hdac2 knockdown effects were transient because Hdac1 appeared to compensate by 12 h, complicating conclusions about Hdac2-specific repression.
- Evident from the text: many mechanistic experiments relied on overexpression or siRNA in HEK293T or primary cells, and the in vivo work used two inflammatory models; the authors note that additional Tet2-repressed mediators may exist in tissue-resident immune cells.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
1 Valid · 0 Not valid · 16 Not checked · 86 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“MS-275 strongly inhibits Hdac1/2 over Hdac3 (ref. 19)”
§ Tet2 is required to resolve inflammation by recruiting Hdac2 to specifically repress IL-6 > Abstract
What the sources say
- Supportedcites [19] Inoue S Mai A Dyer MJ Cohen GM Inhibition of histone deacetylase class I but not class II is critical for the sensitization of leukemic cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. Cancer Res 2006 66 6785 6792 16818655 source
In the Results section 'Expression of HDACs in CLL cells and various cell lines', our copy reports that MS-275 (1-2.5 micromol/L) inhibited HDAC1 and HDAC2 activities by ~50-70% whereas 1 micromol/L did not inhibit HDAC3 (~20% only at 2.5 micromol/L), and explicitly frames the experiment as confirming that 'MS-275 was selectively inhibiting HDAC1 and HDAC2 rather than HDAC3'. The same section also states MS-275 preferentially inhibits HDAC1 (IC50 ~0.3 micromol/L) versus HDAC3 (IC50 ~8 micromol/L), though that IC50 comparison is itself credited to ref. 32; the paper's own immunoprecipitation/activity data carry the claim. Thus the paraphrase 'strongly inhibits Hdac1/2 over Hdac3' matches what this source attributes to MS-275. (LLM, conf=0.86)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“overexpressed Tet2 recruited more endogenous Hdac2 to the Il6 promoter”
§ Tet2 is required to resolve inflammation by recruiting Hdac2 to specifically repress IL-6 > Abstract
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Attenuated histone deacetylation in Tet2-deficient cells was also observed at late phase during LPS response”
§ Tet2 is required to resolve inflammation by recruiting Hdac2 to specifically repress IL-6 > Abstract
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“loss of Tet2 caused higher expression of IFN-γ in activated CD8+ T cells”
§ Tet2 is required to resolve inflammation by recruiting Hdac2 to specifically repress IL-6 > Abstract
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Loss of Tet2 barely affects TLR4 signalling pathways”
§ Tet2 is required to resolve inflammation by recruiting Hdac2 to specifically repress IL-6 > Extended Data
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
45 more claims
Create a free account to see all 103 claims and to verify the 15 references still open.
- It may state two separate claims as one. 31
- Probably not a substantial claim. 28
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“mice deficient in Tet2 developed more severe inflammation in several tissues upon challenge with bacterial endotoxin”
From Clonal hematopoiesis in human aging and disease (2019) · cites this paper as [91]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“this effect on Il6 expression was independent of the catalytic function of Tet2”
From Clonal hematopoiesis in human aging and disease (2019) · cites this paper as [91]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“loss of TET2, an enzyme that catalyzes DNA demethylation, results in prolonged and high expression of proinflammatory cytokines, including IL-6 [180].”
From Transition from inflammation to proliferation: a critical step during wound healing (2016) · cites this paper as [180]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“As CHIP-associated mutations are known to alter the development and function of myeloid cells”
From Clonal hematopoiesis is associated with protection from Alzheimer’s disease (2023) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These results contrast with findings in peripheral macrophages after intraperitoneal injection in vivo (Zhang et al., 2015).”
From TET2 Regulates the Neuroinflammatory Response in Microglia (2019) · cites this paper as Zhang et al., 2015
Experimental — accuracy not yet measured
20 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Conversion of 5-Methylcytosine to 5-Hydroxymethylcytosine in Mammalian DNA by MLL Partner TET1
Tahiliani, M., Koh, K. P., Shen, Y., Pastor, W. A., Bandukwala, H., Brudno, Y., Agarwal, S., Iyer, L. M., Liu, D. R., Aravind, L., et al. (2009) · Science · doi:10.1126/science.1170116 · Cited by 5,836
Cytokines in inflammatory bowel disease
Neurath, M. F. (2014) · Nature Reviews Immunology · doi:10.1038/nri3661 · Cited by 2,706
IL-6 as a keystone cytokine in health and disease
Hunter, C. A., & Jones, S. A. (2015) · Nature Immunology · doi:10.1038/ni.3153 · Cited by 2,511
Ito, S., D’Alessio, A. C., Taranova, O. V., Hong, K., Sowers, L. C., & Zhang, Y. (2010) · Nature · doi:10.1038/nature09303 · Cited by 2,373
TET enzymes, TDG and the dynamics of DNA demethylation
Kohli, R. M., & Zhang, Y. (2013) · Nature · doi:10.1038/nature12750 · Cited by 1,623
Suppression of inflammation by a synthetic histone mimic
Nicodeme, E., Jeffrey, K. L., Schaefer, U., Beinke, S., Dewell, S., Chung, C.-W., Chandwani, R., Marazzi, I., Wilson, P., Coste, H., et al. (2010) · Nature · doi:10.1038/nature09589 · Cited by 1,563
Gene-specific control of inflammation by TLR-induced chromatin modifications
Foster, S. L., Hargreaves, D. C., & Medzhitov, R. (2007) · Nature · doi:10.1038/nature05836 · Cited by 1,344
Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation
Moran-Crusio, K., Reavie, L., Shih, A., Abdel-Wahab, O., Ndiaye-Lobry, D., Lobry, C., Figueroa, M. E., Vasanthakumar, A., Patel, J., Zhao, X., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.06.001 · Cited by 1,339
Self-citationImpaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2
Ko, M., Huang, Y., Jankowska, A. M., Pape, U. J., Tahiliani, M., Bandukwala, H. S., An, J., Lamperti, E. D., Koh, K. P., Ganetzky, R., et al. (2010) · Nature · doi:10.1038/nature09586 · Cited by 1,213
Distinct Effects of T-bet in T H 1 Lineage Commitment and IFN-γ Production in CD4 and CD8 T Cells
Szabo, S. J., Sullivan, B. M., Stemmann, C., Satoskar, A. R., Sleckman, B. P., & Glimcher, L. H. (2002) · Science · doi:10.1126/science.1065543 · Cited by 1,172
Cited by
Items 401–500 of 797
Clonal Hematopoiesis of Indeterminate Potential in Crohn’s Disease and Ulcerative Colitis
Selvan, M. E., Nathan, D. I., Guisado, D., Collatuzzo, G., Iruvanti, S., Boffetta, P., Mascarenhas, J. O., Hoffman, R., Cohen, L. J., Marcellino, B. K., et al. (2025) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izae312 · Cited by 24
Ishihara, R., Watanabe, R., Shiomi, M., Fujita, Y., Katsushima, M., Fukumoto, K., Yamada, S., & Hashimoto, M. (2025) · Biomolecules · doi:10.3390/biom15111586 · Cited by 24
Yan, H., Tan, L., Liu, Y., Huang, N., Cang, J., & Wang, H. (2020) · Clinical Epigenetics · doi:10.1186/s13148-020-00892-8 · Cited by 22
Self-citationHIV-1 Vpr activates host CRL4-DCAF1 E3 ligase to degrade histone deacetylase SIRT7
Zhou, X., Monnie, C. M., DeLucia, M., & Ahn, J. (2021) · Virology Journal · doi:10.1186/s12985-021-01514-2 · Cited by 24
Myeloid-Derived Suppressor Cells: New Insights into the Pathogenesis and Therapy of MDS
Velegraki, M., Stiff, A. R., Papadaki, H. Α., & Li, Z. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11164908 · Cited by 21
“For example, TET2 appears to negatively regulate IL-6 via the recruitment of HDAC2, suggesting that MDS-related inactivating TET2 mutations could lead to increased IL-6 expression [70].”
BackgroundEpigenetic Modification of Cytosines in Hematopoietic Differentiation and Malignant Transformation
An, J., & Ko, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021727 · Cited by 24
Zhao, H., & Deininger, M. W. (2023) · Blood · doi:10.1182/blood.2022017152 · Cited by 23
Gao, Y., Liang, Z., Mao, B., Zheng, X., Shan, J., Jin, C., Liu, S., Kolliputi, N., Chen, Y., Xu, F., et al. (2023) · Journal of Advanced Research · doi:10.1016/j.jare.2023.06.008 · Cited by 20
Li, H., Lu, T., Sun, W., Ma, R., Zhong, H., Wei, Y. Z., Chen, D., Wen, Y., Carlsten, C., & Wen, W. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02271 · Cited by 20
“(24) established that several inflammatory mediators, including IL-6, were significantly upregulated in TET-silenced DCs.”
BackgroundHelicobacter pylori Infection of Primary Human Monocytes Boosts Subsequent Immune Responses to LPS
Frauenlob, T., Neuper, T., Mehinagic, M., Dang, H.-H., Boraschi, D., & Horejs‐Hoeck, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.847958 · Cited by 21
TET-2 up-regulation is associated with the anti-inflammatory action of Vicenin-2
Hassan, N., Ali, A. Y., Withycombe, C. E., Ahluwalia, M. K., Al-Nasseri, R. H., Tonks, A., & Morris, K. (2018) · Cytokine · doi:10.1016/j.cyto.2018.03.016 · Cited by 20
“[14] demonstrated that LPS induces activation of TET-2 and that this event is critical to the resolution of the inflammatory response in macrophages.”
BackgroundInfluentialClonal Hematopoiesis and Premalignant Diseases
Kaner, J. D., Desai, P. M., Mencia-Trinchant, N., Guzmán, M. L., Roboz, G. J., & Hassane, D. C. (2019) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a035675 · Cited by 21
“, IL-1, IL-6, TNFα, CCL-5, CXCL9) (Zhang et al. 2015; Fuster et al. 2017; Cai et al. 2018; Sano et al. 2018).”
BackgroundLu, X., Jin, P., Tang, Q., Zhou, M., Xu, H., Su, C., Wang, L., Xu, F., Zhao, M., Yin, Y., et al. (2025) · Advanced Science · doi:10.1002/advs.202412109 · Cited by 32
The RNA-binding E3 ligase MKRN2 selectively disrupts Il6 translation to restrain inflammation
Zhou, Y., Li, X., Huang, J., Pan, J., Cheng, J., Liu, P., Yang, M., Chen, T., Zhang, Q., Zhou, Y.-M., et al. (2025) · Nature Immunology · doi:10.1038/s41590-025-02183-x · Cited by 23
Self-citationSun, Q., Shen, M., Zhu, S., Liao, Y., Zhang, D., Sun, J., Guo, Z.-Q., Wu, L., Xiao, L., & Liu, L. (2023) · Hepatology International · doi:10.1007/s12072-023-10544-7 · Cited by 21
“TET2 recruits histone deacetylase 2 to specifically repress the IL-6-Janus kinase (JAK)- signal transducer and activator of transcription 3 (STAT3) pathway [24, 25], removing CD38 suppression.”
BackgroundCXCR1 drives the pathogenesis of EAE and ARDS via boosting dendritic cells-dependent inflammation
Zhuang, W., Zhou, J., Zhong, L., Lv, J., Zhong, X., Liu, G., Xie, L., Wang, C., Saimaier, K., Han, S., et al. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-06126-y · Cited by 21
“Thus, it is important to study molecular mechanisms that mediate DC activation and cytokines secretion function for identifying the underlying mechanisms [14 – 16].”
Self-citationPei, L., Zhao, F., & Zhang, Y. (2023) · APOPTOSIS · doi:10.1007/s10495-023-01873-x · Cited by 20
“Several studies have reported a role for HDAC2 in immune-related modulations [43, 44].”
Backgroundα-Ketoglutarate for Preventing and Managing Intestinal Epithelial Dysfunction
Iniguez, A. B., Du, ., & Zhu, M. J. (2024) · Advances in Nutrition · doi:10.1016/j.advnut.2024.100200 · Cited by 21
“Mice lacking TET2 exhibited exacerbated symptoms, increased in fl ammation, and higher IL-6 expression after exposure to DSS compared to wild-type counterparts [156].”
BackgroundFueling Type I Interferonopathies: Regulation and Function of Type I Interferon Antiviral Responses
Ng, C. S., Kato, H., & Fujita, T. (2019) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2019.0037 · Cited by 20
Low shear stress-induced endothelial mesenchymal transformation via the down-regulation of TET2
Li, A., Tan, L.-L., Zhang, S., Tao, J., Wang, Z., & Wei, D. (2021) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2021.01.062 · Cited by 18
Du, W., Chen, D., Wei, K., Yu, D., Gan, Z., Xu, G., & Yao, G. (2023) · The Tohoku Journal of Experimental Medicine · doi:10.1620/tjem.2023.j028 · Cited by 18
Cheng, T., Zhou, C., Bian, S., Sobeck, K., & Liu, Y. (2024) · Cancer Cell International · doi:10.1186/s12935-024-03288-3 · Cited by 22
“S5e; https://string-db.org), which was consistent with previous studies showing that HDAC2 and TET2 are co-transcription factors of DNMT3a [30–32].”
ResultSelf-citationInflammation in myelodysplastic syndrome pathogenesis
Rodríguez‐Sevilla, J. J., & Colla, S. (2024) · Seminars in Hematology · doi:10.1053/j.seminhematol.2024.09.005 · Cited by 20
Mahajan, V., Farquhar, C. M., & Ponnampalam, A. P. (2019) · Molecular Reproduction and Development · doi:10.1002/mrd.23299 · Cited by 18
Clonal Hematopoiesis of Indeterminate Potential as a Novel Risk Factor for Donor-Derived Leukemia
Burns, S. S., & Kapur, R. (2020) · Stem Cell Reports · doi:10.1016/j.stemcr.2020.07.008 · Cited by 23
“For example, loss of Tet2 andDnmt3a inmice promotes inflammation (Cai et al., 2018; Cull et al., 2017; Leoni et al., 2017; Zhang et al., 2015).”
BackgroundQin, W., Brands, X., Veer, C. V. ′., de Vos, A. F., Scicluna, B. P., & van der Poll, T. (2020) · Infection and Immunity · doi:10.1128/iai.00603-20 · Cited by 18
“stimulation with bacterial components (6, 7).”
BackgroundInfluentialImportance of clonal hematopoiesis in heart failure
Chavkin, N. W., Min, K.-D., & Walsh, K. X. (2021) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2021.04.005 · Cited by 20
An Assessment on Ethanol-Blended Gasoline/Diesel Fuels on Cancer Risk and Mortality
Mueller, S., Dennison, G., & Liu, S. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18136930 · Cited by 19
One genome, many cell states: epigenetic control of innate immunity
Fraschilla, I. R., Amatullah, H., & Jeffrey, K. L. (2022) · Current Opinion in Immunology · doi:10.1016/j.coi.2022.102173 · Cited by 20
El-Harakeh, M., Saliba, J. L., Aldeen, K. S., Haidar, M., El‐Hajjar, L., Awad, M. K., Hashash, J. G., Shirinian, M., & El-Sabban, M. E. (2022) · World Journal of Gastroenterology · doi:10.3748/wjg.v28.i40.5845 · Cited by 17
COVID-19 and the Genetics of Inflammation
Choudhri, Y., Maslove, D. M., & Rauh, M. J. (2023) · Critical Care Medicine · doi:10.1097/ccm.0000000000005843 · Cited by 20
“Approximately 76% of myeloid CH (M-CH) variants confer loss of function in DNMT3A and TET2 (36), which are involved in the epigenetic regulation of IFN-I and proinflammatory cytokine (IL-6 and IL-1β) secretion from macrophages, dendritic cells, and other myeloid cells (37, 40, 41).”
BackgroundSMYD3 activates the TCA cycle to promote M1-M2 conversion in macrophages
Zhu, W., Liu, L., Wu, J., Gao, R., Fu, L., Xiao-hong, Y., Zou, Y., Zhang, S., & Luo, D. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.111329 · Cited by 18
Cobaleda, C., Godley, L. A., Nichols, K. E., Włodarski, M. W., & Sánchez-García, I. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-1091 · Cited by 23
The Role of Tet2-mediated Hydroxymethylation in Poststroke Depression
Wei, X., Yu, L., Zhang, Y., Li, X., Wu, H., Jiang, J., Qing, Y., Miao, Z., & Fang, Q. (2021) · Neuroscience · doi:10.1016/j.neuroscience.2021.02.033 · Cited by 17
Self-citationSomatic Mutations in Normal Tissues: New Perspectives on Early Carcinogenesis
Herms, A., & Jones, P. H. (2023) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-061421-012447 · Cited by 20
Wang, X., Liu, X., Duan, X., Zhu, K., Zhang, S., Gan, L., Liu, N., Jaypaul, H., Makamure, J., Ming, Z., et al. (2018) · Acta Dermato Venereologica · doi:10.2340/00015555-2926 · Cited by 18
“Mice received a daily topical dose of 62.5 mg 5% IMQ cream (Mingxin Pharmaceuticals, Sichuan, China) on shaved backs for 7 consecutive days and a subcutaneous injection of the same dose of sh-sc; ( iii ) IMQ+sh-TET2 group ( n = 8), mice received a subcutaneous injection of lentiviral shRNAs targeting TET2 (sh-TET2, Ge…”
InfluentialEmerging role of protein modification in inflammatory bowel disease
Wang, G., Yuan, J., Luo, J., Ocansey, D. K. W., Zhang, X., Qian, H., Xu, W., & Mao, F. (2022) · Journal of Zhejiang University SCIENCE B · doi:10.1631/jzus.b2100114 · Cited by 21
“HDAC2 inhibits the transcrip‑ tion of IL-6 and other inflammatory factors through histone deacetylation (Zhang et al., 2015).”
BackgroundSelf-citationAdverse Reaction to COVID-19 mRNA Vaccination in a Patient With VEXAS Syndrome
Ciprian, G. (2022) · Cureus · doi:10.7759/cureus.23456 · Cited by 16
“These variations often result in the upregulation of pro-inflammatory cytokines such as IL-6 and IL-1, causing systemic inflammation [15].”
BackgroundClinical Importance of Clonal Hematopoiesis in Metastatic Gastrointestinal Tract Cancers
Diplas, B. H., Ptashkin, R. N., Chou, J. F., Sabwa, S., Foote, M. B., Rousseau, B., Argilés, G., White, J. R., Stewart, C. M., Bolton, K. L., et al. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.54221 · Cited by 20
Tet2 regulates Sin3a recruitment at active enhancers in embryonic stem cells
Flores, J. C., Sidoli, S., & Dawlaty, M. M. (2023) · iScience · doi:10.1016/j.isci.2023.107170 · Cited by 17
“Tet2 also interacts with Hdac2 in immune cells and facilitates the deacetylation of histone H3 to silence proinflammatory genes.(21)”
BackgroundNardacchione, E. M., Tricarico, P. M., de Moura, R. R., D’Adamo, P., Thasneem, A., Suleman, M., Marzano, A. V., Crovella, S., & Moltrasio, C. (2023) · Genes · doi:10.3390/genes15010038 · Cited by 17
ATG5 attenuates inflammatory signaling in mouse embryonic stem cells to control differentiation
Li, S., Sun, J., Zhang, B.-W., Yang, L., Wan, Y.-C., Chen, B., Xu, N., Xu, Q., Fan, J., Shang, J.-N., et al. (2024) · Developmental Cell · doi:10.1016/j.devcel.2024.01.026 · Cited by 16
Parkinson’s disease is associated with clonal hematopoiesis with TET2 mutation
Woo, K. A., Kim, H., Lee, C. Y., Shin, J. H., Sun, C.-H., Im, H., An, H., Lim, J., Choi, S., Koh, Y., et al. (2024) · npj Parkinson s Disease · doi:10.1038/s41531-024-00784-1 · Cited by 19
Fondelli, F., Willemyns, J., Domenech-Garcia, R., Mansilla, M. J., Godoy‐Tena, G., Ferreté-Bonastre, A. G., Agúndez-Moreno, A., Presas‐Rodríguez, S., Ramo-Tello, C. M., Ballestar, E., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci178949 · Cited by 19
“In particular, DNA methylation is an epigenetic mark of key importance in myeloid cell plasticity, differentiation, transcription factor activity, and function (25, 26), and its alterations have been tightly linked to inflammation (27) and autoimmune diseases like MS (28, 29).”
Yue, K., Sun, S., Yin, Z., Liu, E., Jia, G., Jiang, Y., Duan, Y., Chen, Y., & Li, X. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c02883 · Cited by 18
Self-citationImpact of TET2 deficiency on iron metabolism in erythroblasts
Inokura, K., Fujiwara, T., Saito, K., Iino, T., Hatta, S., Okitsu, Y., Fukuhara, N., Onishi, Y., Ishizawa, K., Shimoda, K., et al. (2017) · Experimental Hematology · doi:10.1016/j.exphem.2017.01.002 · Cited by 17
Zhang, P., Chen, X., Zhang, Y., Su, H., Zhang, Y., Zhou, X., Sun, M., Li, L., & Xu, Z. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.116601 · Cited by 16
Impact of Host, Lifestyle and Environmental Factors in the Pathogenesis of MPN
Ramanathan, G., Hoover, B., & Fleischman, A. G. (2020) · Cancers · doi:10.3390/cancers12082038 · Cited by 22
Clonal hematopoiesis and vascular disease
Amancherla, K. V., Wells, J. A., & Bick, A. G. (2022) · Seminars in Immunopathology · doi:10.1007/s00281-022-00913-z · Cited by 18
“Using Tet2-/- mice and transferring their bone marrow to that of Ldlr-/- mice, which are prone to atherosclerosis due to knockout of the LDL receptor, Jaiswal et al.”
BackgroundInfluentialÄijö, T., Theofilatos, D., Cheng, M., Smith, M. D., Xiong, Y., Baldwin, A. S., & Tsagaratou, A. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.940995 · Cited by 16
“Moreover, TET2 has been reported to regulate inflammatory phenotypes in macrophages by mechanisms that are not related to its enzymatic activity (49).”
BackgroundGao, S., Qi, X., Li, J., & Sang, L. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.05.143 · Cited by 16
Tsagaratou, A. (2021) · Immunological Reviews · doi:10.1111/imr.12940 · Cited by 18
Isocitrate Dehydrogenase Mutations in Cancer: Mechanisms of Transformation and Metabolic Liability
Gunn, K., & Losman, J.-A. (2024) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041537 · Cited by 17
Ali, A., Jori, C., Kanika, Kumar, A., Vyawahare, A., Kumar, J. S., Kumar, B., Ahmad, A., Fareed, M., Ali, N., et al. (2024) · Biomaterials Science · doi:10.1039/d4bm00243a · Cited by 17
Liu, X., Wang, X., Liu, N., Zhu, K., Zhang, S., Duan, X., Huang, Y., Jin, Z., Jaypaul, H., Wu, Y. F., et al. (2020) · Molecular Medicine Reports · doi:10.3892/mmr.2020.10989 · Cited by 18
“In addition to mediating the formation of 5-hmc, TeT proteins are involved in gene transcription repression via histone de‐acetylation, which represents a dna methylation-independent epigenetic mechanism (11).”
Xu, Y., Wu, Y., Xiong, Y., Tao, J., Pan, T., Tan, S., Gao, G., Chen, Y., Abbas, N., Getachew, A., et al. (2020) · Nutrition & Metabolism · doi:10.1186/s12986-020-0431-y · Cited by 17
Clonal hematopoiesis and cardiovascular disease in cancer patients and survivors
Fuster, J. J. (2022) · Thrombosis Research · doi:10.1016/j.thromres.2021.12.009 · Cited by 15
Truong, L.-L., Scott, L. J., Pal, R., Jalink, M., Gunasekera, S., & Wijeratne, D. T. (2022) · ecancermedicalscience · doi:10.3332/ecancer.2022.1430 · Cited by 15
“From a cardiovascular perspective, CHIP is associated with accelerated atherosclerosis, as genes encoded by CHIP are also involved in de-activation of interleukin-6 (IL-6), ultimately leading to increased circulating levels of IL-6 and increased inflammation [14, 15].”
BackgroundTET-dioxygenase deficiency in oncogenesis and its targeting for tumor-selective therapeutics
Guan, Y., Hasipek, M., Tiwari, A. D., Maciejewski, J. P., & Jha, B. K. (2020) · Seminars in Hematology · doi:10.1053/j.seminhematol.2020.12.002 · Cited by 15
Hessam, S., Sand, M. S., Lang, K., Käfferlein, H. U., Scholl, L., Gambichler, T., Skrygan, M., Brüning, T., Stockfleth, E., & Bechara, F. G. (2017) · Dermatology · doi:10.1159/000478043 · Cited by 15
Wang, Y., Lin, C., Yao, C., Amaral, F. M. R., Yu, S., Kao, C., Shih, P., Hou, H., Chou, W., & Tien, H. (2023) · Blood Advances · doi:10.1182/bloodadvances.2022008958 · Cited by 15
Cell of origin epigenetic priming determines susceptibility to Tet2 mutation
Schiroli, G., Kartha, V. K., Duarte, F. M., Kristiansen, T. A., Mayerhofer, C., Shrestha, R., Earl, A., Hu, Y., Tay, T., Rhee, C., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-48508-6 · Cited by 16
Kállai, A., Ungvari, A., Csabán, D., Őrfi, Z., Lehoczki, A., Harasztdombi, J., Yabluchanskiy, A., Benyó, Z., Szappanos, Á., Tarantini, S., et al. (2025) · GeroScience · doi:10.1007/s11357-025-01654-1 · Cited by 16
“TET2 dysfunction therefore leads to higher expression of IL-6, especially in late-stage inflammation, when the inflammatory trigger is already resolved [118].”
Yang, C., Li, Z., Kang, W., Tian, Y., Yan, Y., & Chen, W. (2016) · Gene · doi:10.1016/j.gene.2016.07.025 · Cited by 14
Tie, G., Yan, J., Khair, L., Tutto, A. A., & Messina, L. M. (2020) · Scientific Reports · doi:10.1038/s41598-020-60403-w · Cited by 15
Inflammatory and Immune Disorders Associated with Myelodysplastic Syndromes
Jachiet, V., Fenaux, P., Sevoyan, A., Hakobyan, Y. K., Adès, L., Fain, O., MEKINIAN, A., & GFM, O. B. O. T. M. A. (2021) · Hemato · doi:10.3390/hemato2020019 · Cited by 17
“- The inactivating mutations of TET2 and DNMT3A could favor a pro-inflammatory state of monocytic and macrophagic cells [44,45] and/or modify the activity of CD8 T lymphocytes and the polarization of the CD4 T lymphocytes, since TET2 regulates the methylation of the promoter regions of FOXP3 gene [46] and genes of tra…”
BackgroundValproic acid ameliorates cauda equina injury by suppressing HDAC2 ‐mediated ferroptosis
Kong, Q., Li, F., Sun, K., Sun, X., & Ma, J. (2023) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14524 · Cited by 17
Deciphering the Epigenetic Code in Embryonic and Dental Pulp Stem Cells.
Bayarsaihan, D. (2016) · PubMed Central · Cited by 16
Lin, Y., Li, Z., Hu, T., Liu, J., Li, N., Cao, X., & Liu, S. (2019) · Cellular and Molecular Immunology · doi:10.1038/s41423-018-0195-8 · Cited by 15
Self-citationL’hématopoïèse clonale : un concept émergent à la croisée des spécialités
Danlos, F., Papo, M., & Micol, J. (2019) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2019.05.005 · Cited by 23
The Complexity of TET2 Functions in Pluripotency and Development
Garcia‐Outeiral, V., de la Parte, C., Fidalgo, M., & Guallar, D. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.630754 · Cited by 16
Lyu, R., Zhu, X., Shen, Y., Xiong, L., Liu, L., Liu, H., Wu, F., Argueta, C. E., & Tan, L. (2021) · Epigenetics · doi:10.1080/15592294.2021.1997405 · Cited by 16
“On the other hand, TET2 may suppress transcriptional overactivation through recruiting Sin3A and HDAC1/2 co-repressor complex to specific gene as reported previously [28].”
BackgroundEpigenetic roles in clonal hematopoiesis and aging kidney-related chronic kidney disease
Ogura, Y., & Mimura, I. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1281850 · Cited by 14
Zhang, Y., Xun, L., Qiao, R., Jin, S., Zhang, B., Luo, M., Wan, P., Zuo, Z., Song, Z., & Qi, J. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1478374 · Cited by 17
Mechanistic insights into SIRT7 and EZH2 regulation of cisplatin resistance in bladder cancer cells
Cao, Y., Wang, S., Ma, J., Long, M., Ma, X., Yang, X. F., Ji, Y., Tang, X., Liu, J., Chen, L., et al. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-07321-1 · Cited by 13
Self-citationDong, Z., Sepúlveda, H., Arteaga-Vazquez, L. J., Blouin, C., Fernandez, J. A., Binder, M., Chou, W., Tien, H., Patnaik, M. M., Faulkner, G. J., et al. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2413302121 · Cited by 13
“…chromosome missegregation and aneuploidies ( 52 ); and Tet2−/− peritoneal macrophages ( 53 ), Tet2−/− bone - marrow - derived macrophages (BMDM) ( 54 ), Tet iTKO BMDM ( 55 ) and DNMT3A - or TET2 - deficient human monocyte - derived macrophages ( 56 ) all show increased expression of…”
Tan, H. S. V., Jiang, H., & Wang, S. S. Y. (2025) · Annals of Hematology · doi:10.1007/s00277-025-06244-x · Cited by 15
“TET2 has been shown to be important for suppression of IL-6 in inflammation resolution [ 12].”
Qin, W., Brands, X., Matsumoto, H., Butler, J. M., Veer, C. V. ′., de Vos, A. F., Roelofs, J. J. T. H., Scicluna, B. P., & van der Poll, T. (2021) · Cells · doi:10.3390/cells11010082 · Cited by 17
“Expression of Tnf was not influenced by Tet2 deficiency irrespective of the stimulus, which is consistent with a previous study [16].”
BackgroundResultInfluentialLing, S., Xu, B., Luo, Y., Fang, X., Liu, X., Wang, A., Zhou, Y., Zhang, S., Zong, W., Li, W., et al. (2022) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2022.03.035 · Cited by 13
Epigenetic mechanisms of myeloid differentiation in the tumor microenvironment
Rodríguez‐Ubreva, J., García-Gómez, A., & Ballestar, E. (2017) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2017.04.008 · Cited by 14
Cull, A. H., & Rauh, M. J. (2017) · Journal of Leukocyte Biology · doi:10.1189/jlb.5ri0317-083r · Cited by 14
“This group also found that Tet2 recruited Hdac2 to the Il-6 promoter late in LPS-stimulated DCs [61].”
BackgroundInfluentialGSK3β inhibition attenuates LPS-induced IL-6 expression in porcine adipocytes
Wang, L., Li, X., & Wang, Y. (2018) · Scientific Reports · doi:10.1038/s41598-018-34186-0 · Cited by 15
Self-citationHessam, S., Gambichler, T., Skrygan, M., Sand, M. S., Rüddel, I., Scholl, L., & Bechara, F. G. (2018) · European Journal of Dermatology · doi:10.1684/ejd.2018.3369 · Cited by 13
Targeted, Amplicon-Based, Next-Generation Sequencing to Detect Age-Related Clonal Hematopoiesis
Snetsinger, B., Ferrone, C. K., & Rauh, M. J. (2019) · Methods in molecular biology · doi:10.1007/7651_2019_216 · Cited by 14
TET2 missense variants in human neoplasia. A proposal of structural and functional classification
Bussaglia, E., Antón, R. I., Nomdedeu, J. F., & Fuentes‐Prior, P. (2019) · Molecular Genetics & Genomic Medicine · doi:10.1002/mgg3.772 · Cited by 16
“For instance, TET2 involvement in the resolution of inflammation depends upon the ability of the enzyme to recruit the histone deacetylase, HDAC2, to specifically repress IL‐6 transcription (Zhang et al., 2015).”
BackgroundZhang, M., Zhang, K., Wang, J., Liu, Y., Liu, G., Jin, W., Wu, S., & Zhao, X. (2020) · Cell & Bioscience · doi:10.1186/s13578-020-00473-5 · Cited by 14
Self-citationClonal hematopoiesis in hematopoietic stem cell transplantation
Wilk, C. M., Manz, M. G., & Boettcher, S. (2020) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000631 · Cited by 15
“Zhang Q, Zhao K, Shen Q, et al. Tet2 is required to resolve inflammation by recruiting Hdac2 to specifically repress IL-6.”
BackgroundHu, Y., Chen, X., Ling, Y., Zhou, K., Han, M., Wang, X., Yue, M., & Li, Y. (2023) · PLoS Pathogens · doi:10.1371/journal.ppat.1011550 · Cited by 13
“TET2 regulates the expression of cytokines, such as Il-6, Il-1β, and Cxcl10, produced mainly in the inflammatory resolution stage [40,41,63,64], contributing to the recruitment and activation of immune cells.”
BackgroundBoulet, M., Gilbert, G., Renaud, Y., Schmidt, M., Auxerre-Plantié, E., Bertrand, R., Nan, X., Jurkowski, T. P., Helm, M., Vandel, L., et al. (2023) · eLife · doi:10.7554/elife.91655 · Cited by 13
Karakasis, P., Lefkou, E. E., Pamporis, K., Farmakis, D. T., Patoulias, D., Antoniadis, A. P., Heymans, S. R. B., Filippatos, G. S., & Fragakis, N. (2025) · European Journal of Heart Failure · doi:10.1002/ejhf.3637 · Cited by 15
Potential role of TET2 in gastric cancer cisplatin resistance
Zhou, K., Guo, H., Zhang, J., Zhao, D., Zhou, Y., Zheng, Z., Xu, Y., Li, Y., & Wang, D. (2019) · Pathology - Research and Practice · doi:10.1016/j.prp.2019.152637 · Cited by 12
Self-citationEmerging drugs for the treatment of chronic myelomonocytic leukemia
Perez, J. R., & Bravo, G. M. (2020) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2020.1854224 · Cited by 12
Li, J., Wang, C., Liu, J., Yu, Y., Liu, Y., Peng, Q., Liu, H., & Guan, X. (2021) · Molecular Biology Reports · doi:10.1007/s11033-021-06370-5 · Cited by 12
Self-citationTET2 mutations as a part of DNA dioxygenase deficiency in myelodysplastic syndromes
Gurnari, C., Pagliuca, S., Guan, Y., Ademà, V., Hershberger, C. E., Ni, Y., Awada, H. K., Kongkiatkamon, S., Zawit, M., Coutinho, D. F., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021005418 · Cited by 15
Sunthankar, K. I., Jenkins, M. T., Cote, C. H., Patel, S. B., Welner, R. S., & Ferrell, P. B. (2021) · Leukemia · doi:10.1038/s41375-021-01487-9 · Cited by 13
Epigenetic regulation of inflammation by CxxC domain‐containing proteins*
Onodera, A., Kiuchi, M., Kokubo, K., & Nakayama, T. (2021) · Immunological Reviews · doi:10.1111/imr.13056 · Cited by 13
Han, F., Wang, W., Shi, M. Q., Zhou, H., Yao, Y., Li, C., & Shang, A. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.1093327 · Cited by 12
“During bacterial and viral infections, respectively, TET2 and TET3 have been demonstrated to decrease the expression of proinflammatory cytokines by bringing HDAC1/2 to the promoters of cytokineencoding genes (Zhang et al., 2015; Xue et al., 2016; Fuster et al., 2017).”
BackgroundGaloian, K. A., Luo, S., Qureshi, A. H., Patel, P., Price, R., Morse, A. S., Chailyan, G., Abrahamyan, S. S., & Temple, H. T. (2016) · Molecular and Clinical Oncology · doi:10.3892/mco.2016.1010 · Cited by 13
Nabeshima, R., Nishimura, O., Maeda, T., Shimizu, N., Ide, T., Yashiro, K., Sakai, Y., Meno, C., Kadota, M., Shiratori, H., et al. (2018) · eLife · doi:10.7554/elife.36435 · Cited by 15
“In addition to functioning as DNA demethylases, Tet proteins associate with Sin3a-Hdac and act as transcriptional repressors in a manner independent of their demethylating activity (Williams et al., 2011; Zhang et al., 2015).”
BackgroundClonal hematopoiesis: Genes and underlying mechanisms in cardiovascular disease development
Haybar, H., Shahrabi, S., Ghanavat, M., & Khodadi, E. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.27752 · Cited by 14
“Tet2−/− macrophages exposed to LDL express increased levels of Cxcl‐1, Cxcl‐2, Cxcl‐3, Pf‐4, IL‐1b, and IL‐6 (Cull, Snetsinger, Buckstein, Wells, & Rauh, 2017; Zhang et al., 2015).”
Background
Metadata
- Authors
- Zhang, Q., Zhao, K., Shen, Q., Han, Y., Gu, Y., Li, X., Zhao, D., Liu, Y., Wang, C., Zhang, X., Su, X., Liu, J., Ge, W., Levine, R. L., Li, N., & Cao, X.
- Affiliations
- Second Military Medical University (CN)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Memorial Sloan Kettering Cancer Center (US)
- Corresponding author
- Cao, Xuetao
- ORCID
- Venue
- Nature
- Published
- 2015-08-19
- Volume
- 525
- Issue
- 7569
- Pages
- 389-393
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC4697747
- OpenAlex
- W1171241794
- Cited by
- 807
- References
- 30
- Citations by year
- 2026: 56 · 2025: 77 · 2024: 83 · 2023: 89 · 2022: 93 · 2021: 82 · 2020: 79 · 2019: 85 · 2018: 62 · 2017: 50 · 2016: 43 · 2015: 7
- FWCI
- 23.46
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Cancer Institute (R01CA173636, P30CA008748)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
- Life Sciences › Immunology and Microbiology › Immunology › Immune Response and Inflammation
- Keywords
- TET2, HDAC2, interleukin-6, inflammation resolution, histone deacetylation, transcriptional repression, 5-hydroxymethylcytosine, IκB, lipopolysaccharide, dendritic cells, macrophages, endotoxic shock, DSS-induced colitis
- MeSH terms
- Interleukin-6 Inhibitors, Acetylation, Animals, Chromatin, Colitis, Dendritic Cells, DNA-Binding Proteins, Female, Histones, Humans, Inflammation, Macrophages, Male, Mice, Inbred C57BL, Promoter Regions, Genetic, Proto-Oncogene Proteins, Transcription, Genetic, Down-Regulation, Interleukin-6, DNA Methylation, I-kappa B Proteins, Epigenesis, Genetic, Dioxygenases, Mice, Histone Deacetylase 2, HEK293 Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-11-12, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-11-12 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.